Topic: Relenza

Dr. Peter McCullough claims that the current strain of bird flu originated from serial passage research at a USDA laboratory in Athens, Georgia. McCullough cites a peer-reviewed paper suggesting the virus was engineered to transmit easily among migratory birds and mammals. He recommends Relenza as a potential prophylactic treatment for influenza-type diseases.

The discussion shifts to antiviral treatments like Tamiflu and Relenza, which are noted for their effectiveness in stopping flu progression if taken early. It is observed that these treatments are rarely mentioned in mainstream news reports compared to vaccines. The segment also covers the process of how flu strains are selected for vaccines based on data from Australia.

Pharmacies across the US are reporting severe shortages of Tamiflu and children's Tylenol during a worsening flu season. While Relenza is a viable alternative, it is rarely mentioned in mainstream media reports. Additionally, an industry whistleblower claims that two nano-lipids used in the Pfizer vaccine were never approved for human use and may be accumulating in the livers of recipients.

The CDC reports a severe H3N2 flu season with hospitalizations doubling in a week. While the flu shot is estimated to be only 30% effective this year, listeners are advised to keep antiviral medications like Relenza or Tamiflu on hand and to practice frequent handwashing as a primary defense.

The current flu season is reported to be widespread across 21 states, with the vaccine estimated to be only 10% effective against the dominant H3N2 strain. Despite the low efficacy, doctors continue to recommend the shot to lessen symptom severity. The hosts discuss personal experiences with the flu and the use of antivirals like Tamiflu and Relenza.

Adam Curry and John C. Dvorak open the show discussing their recent illnesses, comparing symptoms of a widespread flu strain and the effectiveness of antivirals like Relenza and Tamiflu. Dvorak describes his recovery process, which included attending a traditional Russian Orthodox Christmas dinner at Russian House in Austin with Sir Gene, Earl of Texas. The hosts note the timing of the flu epidemic coinciding with the Consumer Electronics Show (CES).

The CDC issued a rare apology, admitting that the 2014-2015 flu vaccine is largely ineffective because the virus mutated. Despite the failure, health officials are urging the use of antiviral drugs like Tamiflu and Relenza, which critics see as a sales pitch for pharmaceutical companies. The hosts discuss the side effects of these drugs and advocate for Vitamin D3 therapy as a more effective preventative measure.

The commercialization of the H1N1 pandemic is examined through services like "Flu Fighters" in the UK, which market vaccinations to businesses to reduce absenteeism. CNN's Sanjay Gupta is criticized for his reporting on contracting swine flu in Afghanistan, which is viewed as a propaganda tool to encourage mass vaccination. The discussion advocates for antivirals like Tamiflu or Relenza over the squalene-adjuvanted vaccine.

Reports suggest Tamiflu may no longer be effective against the Mexican flu, leading to a discussion of Relenza as an alternative powder-based inhalation treatment. Relenza is noted for its unique delivery system involving blister packs and a vortex device. The discussion also highlights Baxter International, a Chicago-based company contracted for vaccine production, and its proximity to political figures in the Obama administration.

The discussion turns to the pharmaceutical industry's management of antiviral drugs like Tamiflu and Relenza. Dvorak notes that older, cheaper generics like Flumidine have largely disappeared from the market, while expensive treatments like Tamiflu face rising resistance. They suggest the current flu scare might be a mechanism to deplete aging stockpiles of medication before they become ineffective.

A Reuters report suggests that the current flu strain is resistant to Tamiflu, though the hosts debate the authenticity of the claim. One host advocates for the use of Tamiflu and Relenza based on personal experience, explaining how the drugs halt viral reproduction. The segment also touches on the CDC's push for vaccinations despite potential stockpiles of ineffective medicine.